PP497 Topic: AS22–Quality and Safety/Errors/Data Management/Other: USE OF SECURACATH IN PREVENTION OF DISPLACEMENT OF LONG-TERM CATHETERS (HICKMAN)

Abstract

Aims & Objectives: Hickman catheters, essential for prolonged administration of Parenteral Nutrition and Medications. The Dacron cuff triggers an inflammatory response, ensuring the secure fixation of the catheter to subcutaneous tissue, a process with variable duration. To address accidental displacement concerns during traction or healing, SecurAcath@ emerges as an advanced solution. Methods: The first three patients reported in the literature who underwent SecurAcath usage for fixing a Hickman central venous catheter (CVC) are presented. Results: 1. One-year-old infant, prematurely,Severe Bronchopulmonary Dysplasia, on Chronic Mechanical Ventilation, A Hickman CVC 6.6 was installed and secured with SecurAcath 7.0. It has remained in place for 142 days (September 1, 2023 - January 20, 2024). 2. Two-year-old infant with PLCG2 genetic mutation. Hypertriglyceridemia necessitating Crystal Insulin for two months, followed by Omegaven therapy for liver disease for three months at home. A Hickman CVC 6.6 was installed with SecurAcath 7.0 at the exit site. It remained in place for 91 days (September 1, 2023 - January 20, 2024) 3. Seven-month and 21-day-old infant, with NALCN gene mutation, Clifahdd Syndrome, on Chronic Mechanical Ventilation. A Hickman CVC 4.2 was installed and secured at the exit site with SecurAcath 4.0 in the PICU. It remained in place for 51 days (October 30, 2023 - January 20, 2024). Conclusions: This is the first report in the literature on the use of SecurAcath in Hickman CVCs, showing promising results in preventing displacement and infection at the insertion site. In addition to these benefits, there may be other advantages similar to those observed with PICC use. Keywords: SecurAcath, sutureless securement, Cost-effectiveness, Central venous catheterization,

Ähnliche Arbeiten